1. Home
  2. VEON vs ACAD Comparison

VEON vs ACAD Comparison

Compare VEON & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VEON Ltd. ADS

VEON

VEON Ltd. ADS

HOLD

Current Price

$64.59

Market Cap

4.2B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.94

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VEON
ACAD
Founded
1992
1993
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.3B
IPO Year
2010
2000

Fundamental Metrics

Financial Performance
Metric
VEON
ACAD
Price
$64.59
$27.94
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$73.40
$30.55
AVG Volume (30 Days)
77.9K
1.4M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.20
Revenue
N/A
$726,437,000.00
Revenue This Year
$12.21
$18.80
Revenue Next Year
$1.60
$11.70
P/E Ratio
$6.15
$141.35
Revenue Growth
N/A
40.45
52 Week Low
$42.60
$19.69
52 Week High
$66.56
$30.96

Technical Indicators

Market Signals
Indicator
VEON
ACAD
Relative Strength Index (RSI) 78.47 48.65
Support Level $48.87 $27.90
Resistance Level N/A $30.96
Average True Range (ATR) 2.04 0.84
MACD 0.61 -0.29
Stochastic Oscillator 97.36 2.18

Price Performance

Historical Comparison
VEON
ACAD

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: